Jeffrey S Elmendorf Selected Research

Actins (F Actin)

1/2019	Excess membrane cholesterol is an early contributing reversible aspect of skeletal muscle insulin resistance in C57BL/6NJ mice fed a Western-style high-fat diet.
8/2017	Exercise training prevents skeletal muscle plasma membrane cholesterol accumulation, cortical actin filament loss, and insulin resistance in C57BL/6J mice fed a western-style high-fat diet.
11/2014	Signaling of the p21-activated kinase (PAK1) coordinates insulin-stimulated actin remodeling and glucose uptake in skeletal muscle cells.
5/2014	Chromium enhances insulin responsiveness via AMPK.
5/2012	AMPK enhances insulin-stimulated GLUT4 regulation via lowering membrane cholesterol.
9/2011	Evidence coupling increased hexosamine biosynthesis pathway activity to membrane cholesterol toxicity and cortical filamentous actin derangement contributing to cellular insulin resistance.
4/2009	Hexosamine biosynthesis pathway flux contributes to insulin resistance via altering membrane phosphatidylinositol 4,5-bisphosphate and cortical filamentous actin.
4/2008	Antidiabetogenic effects of chromium mitigate hyperinsulinemia-induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance.
11/2006	Loss of cortical actin filaments in insulin-resistant skeletal muscle cells impairs GLUT4 vesicle trafficking and glucose transport.
6/2005	Phosphatidylinositol 4,5-bisphosphate reverses endothelin-1-induced insulin resistance via an actin-dependent mechanism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey S Elmendorf Research Topics

Disease

18	Insulin Resistance 01/2022 - 01/2003
7	Hyperinsulinism (Hyperinsulinemia) 05/2014 - 11/2006
6	Type 2 Diabetes Mellitus (MODY) 01/2022 - 06/2004
2	Glucose Intolerance 01/2022 - 08/2008
1	Alzheimer Disease (Alzheimer's Disease) 01/2018
1	Hypercholesterolemia 11/2006
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2006
1	Obesity 06/2004

Drug/Important Bio-Agent (IBA)

13	Insulin (Novolin)FDA Link 01/2022 - 06/2004
10	CholesterolIBA 01/2019 - 11/2006
10	Actins (F Actin)IBA 01/2019 - 06/2005
8	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 11/2006
5	Phosphatidylinositols (Phosphatidylinositol)IBA 09/2011 - 09/2004
4	HexosaminesIBA 03/2013 - 04/2009
3	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 11/2017 - 11/2014
3	Glucosamine (Dona)IBA 09/2011 - 01/2003
3	ChromiumIBA 05/2011 - 11/2006
3	LipidsIBA 04/2008 - 06/2004
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2013
2	Endothelins (Endothelin)IBA 08/2006 - 06/2005
1	Amyloid (Amyloid Fibrils)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	MicronutrientsIBA 05/2014
1	DNA (Deoxyribonucleic Acid)IBA 03/2013
1	DiazooxonorleucineIBA 03/2013
1	Carrier Proteins (Binding Protein)IBA 03/2013
1	LuciferasesIBA 03/2013
1	Plicamycin FDA Link 03/2013
1	SterolsIBA 03/2013
1	Oxidoreductases (Dehydrogenase)IBA 03/2013
1	AcetylglucosamineIBA 03/2013
1	Messenger RNA (mRNA)IBA 03/2013
1	ApolipoproteinsIBA 05/2011
1	HDL CholesterolIBA 05/2011
1	AMP-Activated Protein KinasesIBA 05/2011
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 05/2011
1	Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)IBA 04/2009
1	Adenosine Triphosphate (ATP)IBA 04/2009
1	picolinic acid (chromium picolinate)IBA 08/2008
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 08/2008
1	methyl-beta-cyclodextrinIBA 04/2008
1	Biological ProductsIBA 06/2004
1	Glucose Transporter Type 4IBA 06/2004
1	Insulin ReceptorIBA 06/2004

Therapy/Procedure

2	Therapeutics 08/2008 - 11/2006